Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
NCT ID: NCT06771128
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
398 participants
INTERVENTIONAL
2024-11-01
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ginko Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
NCT06772584
Desmopressin Monotherapy for Monosymptomatic Nocturnal Enuresis
NCT06285006
Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population
NCT02584231
Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
NCT05617664
Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.
NCT06185361
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.
One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.
On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.
Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.
the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ginkgo Biloba group
Patients in this group receive Ginkgo Biloba oral tablet.
Ginkgo Biloba oral tablet
patients receive Ginkgo Biloba oral tablet 120 mg once daily
Desmopressin like Placebo
patients receive Desmopressin like Placebo oral tablet once daily
Desmopressin group
Patients in this group receive Desmopressin oral tablets.
Desmopressin Acetate 0.2 mg Tablets
patient receives desmopressin 0.2 mg oral tablet once daily
Ginkgo Biloba like Placebo
patients receive Ginkgo Biloba like Placebo oral tablet once daily
Combination group
Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.
Ginkgo Biloba oral tablet
patients receive Ginkgo Biloba oral tablet 120 mg once daily
Desmopressin Acetate 0.2 mg Tablets
patient receives desmopressin 0.2 mg oral tablet once daily
Placebo group
Patients in this group receive Placebo oral tablet.
Ginkgo Biloba like Placebo
patients receive Ginkgo Biloba like Placebo oral tablet once daily
Desmopressin like Placebo
patients receive Desmopressin like Placebo oral tablet once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ginkgo Biloba oral tablet
patients receive Ginkgo Biloba oral tablet 120 mg once daily
Desmopressin Acetate 0.2 mg Tablets
patient receives desmopressin 0.2 mg oral tablet once daily
Ginkgo Biloba like Placebo
patients receive Ginkgo Biloba like Placebo oral tablet once daily
Desmopressin like Placebo
patients receive Desmopressin like Placebo oral tablet once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
5 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menoufia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ammar Fathi Mohamed AlOrabi
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Menoufia Faculty of Medicine
Shebin El-Kom, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ginkgo Biloba vs Desmopressin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.